Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate

Author:

Stamatis Pavlos12ORCID,Turkiewicz Aleksandra3ORCID,Englund Martin3ORCID,Turesson Carl4ORCID,Mohammad Aladdin J135ORCID

Affiliation:

1. Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden

2. Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Greece

3. Department of Clinical Sciences Lund, Clinical Epidemiology Unit, Sweden

4. Department of Clinical Sciences Malmö, Rheumatology, Lund University, Sweden

5. Department of Medicine, University of Cambridge, Cambridge, UK

Abstract

Abstract Objective To characterize the epidemiology of temporal artery biopsy-positive (TAB+) GCA, including trends in incidence, seasonal variation and prevalence in Skåne, the southernmost region of Sweden. Methods All histopathology reports of TABs from 1997 through 2019 were reviewed to identify patients diagnosed with TAB+ GCA. Incidence rates based on the 23-year period and the point-prevalence at 31 December 2014 were determined. An alternative prevalence calculation included only TAB+ GCA patients living in the study area and receiving immunosuppressant therapy on the point-prevalence date. Results One thousand three hundred and sixty patients were diagnosed with TAB+ GCA (71% female). The average annual incidence 1997–2019 was 13.3 (95% CI: 12.6, 14.0) per 100 000 inhabitants aged ≥50 years and was higher in females (17.8; 95% CI: 16.7, 18.9) than in males (8.2; 95% CI: 7.4, 9.0). The age- and sex-standardized incidence declined from 17.3 in 1997 to 8.7 in 2019, with incidence ratio (IR) of 0.98 per year (95% CI: 0.98, 0.99). A seasonal variation was observed with higher incidence during spring than winter [IR = 1.19 (95% CI: 1.03, 1.39)]. The overall point-prevalence of TAB+ GCA was 127.1/100 000 (95% CI: 117, 137.3) and was 75.5 (95% CI: 67.7, 83.3) when including only patients receiving immunosuppressants. Conclusion Over the past 2 decades, the incidence of biopsy-confirmed GCA has decreased by ∼2% per year. Still, a high prevalence of GCA on current treatment was observed. More cases are diagnosed during spring and summer than in the winter.

Funder

Swedish Research Council

King Gustaf V's 80-year foundation

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Reference47 articles.

1. 2012 revised international chapel hill consensus conference nomenclature of vasculitides;Jennette;Arthritis Rheum,2013

2. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease;Dejaco;Rheumatology (Oxford),2017

3. The incidence of giant cell arteritis in Slovenia;Pucelj;Clin Rheumatol,2019

4. Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial;Tuckwell;Semin Arthritis Rheum,2017

5. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice;Dejaco;Ann Rheum Dis,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3